FDA accepted NDA for zidesamtinib for the treatment of TKI pre-treated patients with advanced ROS1-positive NSCLC; PDUFA target action date of September ...

From new imaging and targeted therapies to patient journeys, 2025 highlighted key advances and personal stories in lung ...

Then you have the fact that clinical trials often underrepresent minorities. This can lead to skewed AI models, with 80 percent of trials facing recruitment delays due to these issues. Given that ...

Two commercialized hematology products, Olverembatinib and Lisaftoclax, drive dual-engine growth with strong China market presenceNext-generation ...

Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC: Rahway, New Jersey Friday, January 9, 2026, 15:00 Hrs [IST] ...

Detailed price information for Denali Therapeutics Inc (DNLI-Q) from The Globe and Mail including charting and trades.

Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated ...

China NMPA grants breakthrough therapy designation to Kelun-Biotech’s sacituzumab tirumotecan in combo with immunotherapy pembrolizumab for first-line treatment of PD-L1-positive NSCLC ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company," 6990.HK) today announced that its ...

An announcement from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( ($HK:6990) ) is now available. Sichuan Kelun-Biotech announced ...

Program will expand access in certain regions where Revuforj is not available commercially, as permitted by local regulations -- Program will ...

Two Complete Metabolic Responses (CMRs) observed in patients with relapsed/refractory metastatic Ewing sarcoma and one Complete Response (CR) observed in a patient with relapsed/refractory metastatic ...